Peter Harrison, Chief Executive, has dealt in the Ordinary Shares of 5 pence each (the “Ordinary Shares”) as follows:
- On 1 April 2020, the sale of 30,000 Ordinary Shares at 3,600 pence per Ordinary Share (the “Sale”); and
- On 2 April 2020, the exercise of options over 18,500 Ordinary Shares at 1,350 pence per Ordinary Share (the “Option Shares”), pursuant to the Company’s 2013 EMI Share Option Scheme (the “Exercise”) (details of which can be found at www.bioventix.com).
Following the Sale and the Exercise, Peter Harrison’s total beneficial interest in the Company will be 416,676 Ordinary Shares representing approximately 8.0% of the Company.
Following the Exercise, the Company has applied for 18,500 Ordinary Shares to be admitted to trading on AIM (“Admission”). It is expected that Admission will occur and that dealings will commence in the Option Shares on 8 April 2020. The Option Shares will rank pari passu with the existing Ordinary Shares.
Click here to read the full press release.